These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

101 related articles for article (PubMed ID: 161880)

  • 1. An unusual case of myeloproliferative disease which started with erythroderma: chronic (incomplete) panmyelosis.
    Gorini M; Ghizzi A; Bobbio Pallavicini E; Perugini S
    Haematologica; 1979 Dec; 64(6):804-11. PubMed ID: 161880
    [No Abstract]   [Full Text] [Related]  

  • 2. Myelofibrosis in myeloproliferative disorders.
    Srinivasan U; Talvalkar GV; Advani SH
    Indian J Cancer; 1978 Sep; 15(3):37-43. PubMed ID: 294411
    [No Abstract]   [Full Text] [Related]  

  • 3. Erythroderma associated with leukocytosis in premalignant myeloproliferative disorder.
    Takatsuka Y; Komine M; Fujita E; Koike Y; Yamada T; Murata S; Ohtsuki M
    Int J Dermatol; 2009 Mar; 48(3):324-6. PubMed ID: 19261028
    [No Abstract]   [Full Text] [Related]  

  • 4. Treatment of myeloproliferative diseases.
    Sellei C
    Ther Hung; 1966; 14(4):135-6. PubMed ID: 5228101
    [No Abstract]   [Full Text] [Related]  

  • 5. The management of elderly patients with myeloproliferative disorders.
    Tura S
    Hematol Oncol; 1993; 11 Suppl 1():39-41. PubMed ID: 8486340
    [No Abstract]   [Full Text] [Related]  

  • 6. [Bioptic medullary findings for the formation of fibres in attended and not yet attended myeloses (author's transl)].
    Hill K; Dennhardt HH
    Verh Dtsch Ges Pathol; 1972; 56():587-92. PubMed ID: 4130904
    [No Abstract]   [Full Text] [Related]  

  • 7. A case of Philadelphia-chromosome positive chronic idiopathic myelofibrosis.
    Chen F; Zhang C; Wang W; Li L; Yan S; Sun J; Zhang M; Ji C; Hou M
    Leuk Res; 2008 Apr; 32(4):665-7. PubMed ID: 17854891
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Busulphan and the lungs. Absence of lung function disturbance in patients treated with busulphan.
    Comhaire F; Van Hove W; Van Ganse W; Van der Straeten M
    Scand J Respir Dis; 1972; 53(5):265-73. PubMed ID: 4508954
    [No Abstract]   [Full Text] [Related]  

  • 9. Mechanism of myelofibrosis in chronic myeloproliferative disorders.
    Yonekura S
    Tokai J Exp Clin Med; 1987 Sep; 12(3):141-5. PubMed ID: 3331217
    [No Abstract]   [Full Text] [Related]  

  • 10. Development of polycythemia vera in a patient with myeloid metaplasia and myelofibrosis. Report of a case with a comment on its significance in relation to prevailing views on myeloid metaplasia.
    Hershko C; Polliack A
    Isr J Med Sci; 1971 Feb; 7(2):315-20. PubMed ID: 5560987
    [No Abstract]   [Full Text] [Related]  

  • 11. [The treatment of myeloproliferative syndromes].
    Maurice P
    Schweiz Med Wochenschr; 1975 Oct; 105(40):1269-74. PubMed ID: 1061995
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Myelofibrosis revisited: characterization and classification of myelofibrosis in the setting of myeloproliferative disease.
    Gilbert HS
    Prog Clin Biol Res; 1984; 154():3-17. PubMed ID: 6382299
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Myeloproliferative diseases in childhood.
    Nix WL; Fernbach DJ
    Am J Pediatr Hematol Oncol; 1981; 3(4):397-407. PubMed ID: 6174053
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Morphological studies on the bone tissue of sternum in osteomyelosclerosis, panmyelosis and chronic myeloleukosis.
    Velizarov A; Valkov I
    Nauchni Tr Vissh Med Inst Sofiia; 1970; 49(3):61-71. PubMed ID: 4253273
    [No Abstract]   [Full Text] [Related]  

  • 15. [Unusual case of chronic myeloproliferative syndrome].
    Tosato F; Fossaluzza V
    Arch Sci Med (Torino); 1982; 139(4):531-5. PubMed ID: 6891999
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Pathogenesis of marrow fibrosis in myeloproliferative disorders].
    Wróbel T; Podolak-Dawidziak M
    Pol Arch Med Wewn; 1998 Jan; 99(1):70-7. PubMed ID: 9686507
    [No Abstract]   [Full Text] [Related]  

  • 17. [Choice of therapy and overall survival in patients with chronic myeloproliferative diseases].
    Rukavitsyn OA; Pop VP; Seriakov AP
    Vopr Onkol; 2004; 50(4):435-9. PubMed ID: 15605767
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Metamorphosis of chronic myeloproliferative diseases].
    Butoianu E; Nicoară S; Coliţă A; Ursea C; Berceanu S
    Rev Med Interna Neurol Psihiatr Neurochir Dermatovenerol Med Interna; 1983; 35(3):223-32. PubMed ID: 6140716
    [No Abstract]   [Full Text] [Related]  

  • 19. Platelet function after busulphan in chronic myeloproliferative disorders.
    Barbui T; Bassan R; Viero P; Cortelazzo S; Dini E
    Haematologica; 1983; 68(4):469-77. PubMed ID: 6414897
    [No Abstract]   [Full Text] [Related]  

  • 20. [Paraneoplastic erythroderma: apropos of a case].
    Faure M; Bertrand C; Mauduit G; Souteyrand P; Thivolet J
    Dermatologica; 1985; 170(3):147-51. PubMed ID: 3156777
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.